These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 19504731)

  • 41. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study.
    Kim KH; Yi J; Lee SH
    Korean J Intern Med; 2015 Sep; 30(5):705-13. PubMed ID: 26354065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children.
    Bunupuradah T; Puthanakit T; Kosalaraksa P; Kerr S; Boonrak P; Prasitsuebsai W; Lumbiganon P; Mengthaisong T; Phasomsap C; Pancharoen C; Ruxrungtham K; Ananworanich J
    AIDS Res Ther; 2011 Oct; 8():40. PubMed ID: 22026962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term outcomes of HIV-infected children in Thailand: the Thailand Pediatric HIV Observational Database.
    Phongsamart W; Hansudewechakul R; Bunupuradah T; Klinbuayaem V; Teeraananchai S; Prasithsirikul W; Kerr SJ; Akarathum N; Denjunta S; Ananworanich J; Chokephaibulkit K
    Int J Infect Dis; 2014 May; 22():19-24. PubMed ID: 24576843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
    Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of highly active antiretroviral therapy in HIV-infected Indian children.
    Mukherjee A; Shah N; Singh R; Vajpayee M; Kabra SK; Lodha R
    BMC Infect Dis; 2014 Dec; 14():701. PubMed ID: 25539905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
    Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.